COMMENTARY

• Japan to See Arrival of 1st Treatment for HFpEF, Will Entresto Meet Unmet Medical Needs?
  July 22, 2020

• Diabetes Market Regaining Momentum with New Launches; First Oral GLP-1 a Game Changer?
  July 13, 2020

• Will Zolgensma Delay Spur Revision of Sakigake Designation System?
  June 11, 2020

• Establish Development Regime to Always Be Prepared for New Infectious Disease, Global Health Confab Urges amid COVID-19
  May 7, 2020

• Blurred Outlook for Off-Year Drug Re-Pricing, Will Japan Go Ahead with April 2021 Plan?
  April 27, 2020

• Drug Rep Number Might Have Logged 5,000-Plus Decrease in 1 Year: Jiho Tally
  April 22, 2020

• Lenvima Heading into Megablockbuster Territory, Will Merck Tie-Up Help It Top Combined Aricept/Pariet Sales?
  March 12, 2020

• Unison Capital Shows Rising Presence with Kyowa Deal, PE Fund Potential Catalyst for Industry Shakeup?
  November 22, 2019

• Finance Officials, Payers Grow Jittery as Xolair’s Pollen Allergy Nod Looms
  November 18, 2019

• Pharma’s Downsizing Bandwagon Shows No Sign of Slowing, Companies Seeking Even Leaner Staff
  October 28, 2019

• Pharma Should Tap Health Coverage Debate as Catalyst to Draw Govt’s Commitment on Innovation
  October 1, 2019

• After Death in First-in-Human Study, MHLW Needs to Release Info. to Alleviate Concerns about Participation in Studies
  August 26, 2019

• Generic Players Step Up Info Disclosure for Survival in Post-80% Era
  July 16, 2019

• Drug Pricing Debate for 2020 Reform Going into High Gear; Industry Leery of Post-Election Surprises
  July 5, 2019

• Filing for Sakigake Radiation Therapy Expected This Year for Head and Neck Cancer; Expanded Use, Overseas Development Eyed
  June 25, 2019

• Cell Therapy Makers Working to Stand Out from Rivals by Reducing Burdens on Hospitals
  April 16, 2019

• Building Credible, Convincing System Holds Key for Japan’s Cost-Effectiveness Assessment
  April 2, 2019

• Generic Makers Shifting to Focus on “Specialty Area” Faced with Tougher Business Environment
  March 4, 2019

• Restructuring, Divestment Progress in Wake of Drug Pricing Overhaul
  February 20, 2019

• 2019 Likely to Herald Burst of “Regenerative Medicine” Approvals
  January 11, 2019

ページ